Stoke Therapeutics/$STOK
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Stoke Therapeutics
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
Ticker
$STOK
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
128
ISIN
US86150R1077
Website
STOK Metrics
BasicAdvanced
$658M
13.75
$0.88
1.20
-
Price and volume
Market cap
$658M
Beta
1.2
52-week high
$15.97
52-week low
$5.35
Average daily volume
561K
Financial strength
Current ratio
8.409
Quick ratio
8.01
Long term debt to equity
0.535
Total debt to equity
1.203
Profitability
EBITDA (TTM)
40.331
Gross margin (TTM)
100.00%
Net profit margin (TTM)
26.33%
Operating margin (TTM)
20.03%
Effective tax rate (TTM)
2.48%
Revenue per employee (TTM)
$1,490,000
Management effectiveness
Return on assets (TTM)
7.81%
Return on equity (TTM)
20.50%
Valuation
Price to earnings (TTM)
13.755
Price to revenue (TTM)
3.595
Price to book
1.88
Price to tangible book (TTM)
1.88
Price to free cash flow (TTM)
9.919
Free cash flow yield (TTM)
10.08%
Free cash flow per share (TTM)
121.59%
Growth
Revenue change (TTM)
2,333.81%
Earnings per share change (TTM)
-136.29%
3-year revenue growth (CAGR)
299.24%
3-year earnings per share growth (CAGR)
-29.81%
What the Analysts think about STOK
Analyst ratings (Buy, Hold, Sell) for Stoke Therapeutics stock.
Bulls say / Bears say
Stoke Therapeutics reported a net income of $112.9 million ($1.90 per diluted share) in Q1 2025, a significant turnaround from a loss in 2024, indicating strong financial performance. (stocktitan.net)
The company secured a collaboration with Biogen, receiving $165 million upfront and potential milestone payments up to $385 million, enhancing its financial stability and growth prospects. (stocktitan.net)
Analysts have set an average 12-month price target of $23.00 for STOK, reflecting confidence in the company's future performance. (americanbankingnews.com)
Insider selling activity, including the sale of 1,937,500 shares by major shareholder Skorpios Trust, may signal concerns about the company's future prospects. (marketbeat.com)
Despite positive earnings, the stock experienced a 7.56% decline following the Q1 2025 financial results announcement, indicating potential investor skepticism. (stocktitan.net)
The company's reliance on the success of its lead investigational medicine, zorevunersen, poses a risk if clinical trials do not meet expectations or face regulatory hurdles. (stocktitan.net)
Data summarised monthly by Lightyear AI. Last updated on 12 Jul 2025.
STOK Financial Performance
Revenues and expenses
STOK Earnings Performance
Company profitability
STOK News
AllArticlesVideos
Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress
GlobeNewsWire·5 days ago
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·4 weeks ago
Stoke Therapeutics to Present at the Jefferies Global Healthcare Conference
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Stoke Therapeutics stock?
Stoke Therapeutics (STOK) has a market cap of $658M as of July 15, 2025.
What is the P/E ratio for Stoke Therapeutics stock?
The price to earnings (P/E) ratio for Stoke Therapeutics (STOK) stock is 13.75 as of July 15, 2025.
Does Stoke Therapeutics stock pay dividends?
No, Stoke Therapeutics (STOK) stock does not pay dividends to its shareholders as of July 15, 2025.
When is the next Stoke Therapeutics dividend payment date?
Stoke Therapeutics (STOK) stock does not pay dividends to its shareholders.
What is the beta indicator for Stoke Therapeutics?
Stoke Therapeutics (STOK) has a beta rating of 1.2. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.